secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001390478-23-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Life Sciences reports FY2022 net loss $41.3M; cash $17.1M, raised $20M in Feb 2023 plus $13M milestone expected
--------------------------------------------------------------------------------

- Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.
- Cash $17.1M at Dec 31, 2022; subsequent $20M public offering gross proceeds in Feb 2023.
- Phase 3 REGAL AML study interim analysis expected late 2023/early 2024.
- $13M milestone payment from 3D Medicines expected in H1 2023.
- Phase 1 of CDK9 inhibitor GFH009 shows no dose-limiting toxicities; first confirmed CR in AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/0001390478-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000006/sls-20230316.htm
  HTML page:      https://secwatch.observer/filing/0001390478-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer